Atropine

According to a 2016 analysis of 145 studies including 2.1 million participants, myopia will affect nearly 50% of the global population by 2050.

WASHINGTON — Optometrists must learn about myopia management and discuss it with parents, according to clinicians participating in a panel discussion at Optometry’s Meeting.

Using 0.05% atropine eyedrops every night for 2 years reduced the incidence of myopia in young children, although researchers acknowledge further study is needed.

Both 0.03% and 0.05% atropine eyedrops significantly enlarged pupil size in photopic and scotopic conditions in children aged 6 to 17 years, with no significant change in binocular vision assessments and visual acuity, according to a study.

Two years of nightly atropine eye drops did not slow myopia progression or axial elongation in a cohort of U.S. children compared with placebo, according to a randomized clinical trial.

NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Mark A. Bullimore, MCOptom, PhD, FAAO, discussed the use of atropine for myopia control in the LAMP study.

As everybody knows, the incidence and prevalence of myopia are increasing in every country around the world.

Myopia, which affects more than 1 billion people worldwide, has become a major global vision concern, and the problem is only getting worse.

Vyluma Inc. has announced that the FDA will review its new drug application for NVK002, a preservative-free, low-dose atropine eye drop for myopia in children aged 3 to 17 years.

Enrollment is underway for a study evaluating the combined use of multifocal contact lenses and 0.01% atropine eye drops in the management of myopia in children, according to a research protocol published in the Eye & Contact Lens.